GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics, following recent collaborations with Sino-US Duality Biologics and US biotech Rgenta Therapeutics. This latest alliance aims to identify and validate novel drug targets for the treatment of Alzheimer’s disease, leveraging insights from Muna’s MiND-MAP platform, which utilizes spatial transcriptomics on brain samples from Alzheimer’s patients and cognitively resilient individuals.
MiND-MAP Platform and Its Role in Alzheimer’s Research
Muna’s MiND-MAP platform applies advanced spatial transcriptomics to analyze brain samples, providing valuable insights into the pathology of Alzheimer’s disease. This technology enables a deeper understanding of the disease’s impact and may uncover new therapeutic targets for drug development.
Financial Terms and Collaboration Structure
Under the agreement, Muna will receive an upfront payment of EUR 33.5 million and is eligible to receive up to EUR 140 million in milestone payments per target, as well as tiered royalties on net sales of products that result from the collaboration. Muna will expand its MiND-MAP dataset and lead the identification and validation of new Alzheimer’s disease targets.
GSK’s Commitment to Drug Development
GSK will take the lead in drug development, managing preclinical activities, clinical development, manufacturing, and commercialization of any products discovered and validated through the collaboration. This strategic partnership combines Muna’s expertise in target identification with GSK’s drug development capabilities, aiming to accelerate the discovery of new treatments for Alzheimer’s disease.-Fineline Info & Tech
